Kisspeptin-10 for Fertility & Hormonal Support

Candidate profile

Adults with functional hypothalamic hypogonadism, unexplained infertility with low gonadotropin levels, or individuals seeking physiological stimulation of the reproductive axis without bypassing hypothalamic regulation. Kisspeptin-10 is most relevant for individuals whose fertility challenges originate at the hypothalamic level — inadequate GnRH pulsatility leading to insufficient LH and FSH secretion.

In the clinical research context, Kisspeptin has been studied primarily in women undergoing IVF as an alternative to hCG for triggering oocyte maturation, with the advantage of dramatically reduced ovarian hyperstimulation syndrome (OHSS) risk. In men, Kisspeptin stimulates the HPT axis upstream of GnRH, providing a more physiological stimulus than direct gonadotropin administration.

This is an investigational peptide with clinical trial data but no regulatory approval for fertility treatment. Use is exploratory.

Approach

Subcutaneous Kisspeptin-10 administration to stimulate GnRH neurons in the hypothalamic arcuate nucleus. Kisspeptin is the endogenous ligand for the GPR54 (KISS1R) receptor, and it serves as the master upstream regulator of the reproductive axis. It triggers GnRH secretion, which in turn stimulates pituitary LH and FSH release. This cascade is the physiological pathway that puberty, ovulation, and reproductive function depend on.

The advantage of stimulating at the kisspeptin level — rather than providing GnRH directly (gonadorelin) or gonadotropins (hCG, FSH) — is that it engages the full physiological cascade with built-in feedback regulation. Overstimulation is self-limiting because the hypothalamic-pituitary feedback loops remain intact.

Protocol design

Primary peptide: Kisspeptin-10, 1.0–6.4 nmol/kg per dose (clinical trial dosing)

Route: Subcutaneous injection or intravenous (IV used in clinical trials for acute testing)

Timing: Protocol-dependent — single bolus for ovulation triggering, or repeated dosing for axis stimulation

For reproductive axis stimulation (investigational):

• Kisspeptin-10, subcutaneous, once to twice daily
• Dose titration based on LH response (blood testing required)
• Cycle length: 2–4 weeks, with gonadotropin monitoring

For IVF oocyte maturation trigger (clinical research protocol):

• Single subcutaneous bolus of Kisspeptin-54 (the longer form used in Dhillo group trials) at 9.6 nmol/kg
• Administered 36 hours before oocyte retrieval, replacing standard hCG trigger
• This application has the strongest clinical evidence (Phase II trials at Imperial College London)

Important: Kisspeptin-10 (the decapeptide fragment) and Kisspeptin-54 (full-length) have different potencies and pharmacokinetics. Clinical IVF trials predominantly use Kisspeptin-54. The shorter Kisspeptin-10 has a faster onset but shorter duration of action.

Expected timeline

Minutes to hours (acute administration): Measurable LH surge within 30–60 minutes of subcutaneous injection. This is well-documented in clinical studies — Kisspeptin produces a robust, dose-dependent LH pulse. FSH elevation is also observed but is less dramatic.

Days 1–7 (repeated dosing): Sustained gonadotropin elevation with repeated administration. In men, testosterone levels rise as downstream Leydig cell stimulation increases. In women, follicular development may be stimulated if baseline gonadotropin levels were suppressed.

Weeks 2–4: Assessment window. If the goal is restoration of hypothalamic GnRH pulsatility, the question is whether repeated Kisspeptin administration can "re-train" the system. Current evidence does not confirm lasting effects after cessation — the axis may return to baseline once exogenous Kisspeptin is withdrawn.

Long-term: Unknown. There are no long-term administration studies. The theoretical concern with chronic use is tachyphylaxis (receptor desensitization), though pulsatile administration may mitigate this.

Concurrent requirements

• Comprehensive fertility workup: Kisspeptin addresses hypothalamic-level dysfunction. It does not help with tubal factors, uterine abnormalities, severe sperm pathology, or ovarian failure. A full fertility evaluation is prerequisite
• Hormonal baseline: LH, FSH, estradiol (women), testosterone (men), prolactin, and thyroid function before initiating. Kisspeptin is most likely to benefit individuals with low-normal gonadotropins
• Medical supervision: This is not a self-administered protocol. The dosing, monitoring, and interpretation require endocrinologist or reproductive endocrinologist oversight
• Lifestyle optimization: Hypothalamic amenorrhea (a primary target for Kisspeptin) is often driven by energy deficit, excessive exercise, or psychological stress. Addressing these causes is necessary — Kisspeptin may restore the signal, but the underlying suppressive factors must be corrected

Monitoring

• LH and FSH: Baseline and serial measurements during treatment. The primary pharmacodynamic endpoint is LH pulse amplitude and frequency
• Estradiol (women) / Testosterone (men): Downstream confirmation that gonadotropin elevation is producing gonadal steroid synthesis
• Ultrasound (women): Follicular development monitoring if the goal is ovulation induction
• Semen analysis (men): If the goal is spermatogenesis restoration, serial semen analyses at baseline, 4 weeks, and 12 weeks (spermatogenesis cycle is approximately 74 days)
• Ovarian hyperstimulation markers (women in IVF): The key clinical advantage of Kisspeptin over hCG triggering is dramatically reduced OHSS risk — but monitoring is still required

What success looks like

In the IVF context, success is oocyte maturation and retrieval with minimal or no OHSS — this is the outcome demonstrated in the Imperial College London clinical trials. Kisspeptin triggering produced comparable oocyte maturation rates to hCG with near-elimination of severe OHSS in high-risk patients.

In the reproductive axis stimulation context, success is measurable elevation of LH, FSH, and downstream sex steroids from a previously suppressed baseline. The ultimate success metric is restoration of ovulatory cycles (women) or normalization of testosterone and spermatogenesis (men).

Success does not mean Kisspeptin is superior to established fertility treatments. It occupies a specific niche — physiological axis stimulation with reduced overstimulation risk — rather than replacing gonadotropins, clomiphene, or assisted reproductive technologies.

Evidence reality check

Kisspeptin has an unusually strong basic science foundation. Its role as the master regulator of GnRH was discovered in 2003, and the mechanistic understanding is detailed and well-replicated. Clinical evidence is concentrated in the IVF trigger application — the group led by Waljit Dhillo at Imperial College London has published Phase I and Phase II trials demonstrating safety and efficacy for oocyte maturation triggering with significantly reduced OHSS rates. This is genuine clinical trial data, not preclinical extrapolation.

However, the broader fertility support application — using Kisspeptin to restore reproductive axis function in hypothalamic hypogonadism — is supported by acute pharmacodynamic studies (it reliably triggers LH pulses) but lacks efficacy trials with pregnancy or sustained hormonal normalization as endpoints. The mechanism is compelling, the acute pharmacology is demonstrated in humans, but the therapeutic application beyond IVF triggering remains investigational.